Findings

What do systematic reviews say?

2 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

High‐dose vs standard‐dose strategies

Bronchopulmonary dysplasia/chronic lung disease · preterm infants at risk for apnea

It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).

1 finding from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.89 [0.61, 1.3]
2 studies · 152 participants
Very low

High‐dose vs standard‐dose strategies

Bronchopulmonary dysplasia/chronic lung disease · preterm infants with or at risk for apnea of prematurity

It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).

3 findings from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.72 [0.47, 1.11]
3 studies · 333 participants
Very low
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.68 [0.48, 0.97]
1 study · 238 participants
Low
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.75 [0.6, 0.94]
5 studies · 723 participants
Moderate